Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
Video content above is prompted by the following questions:
New Protocol to Study Brain Stimulation With Virtual Reality in MS
December 11th 2025Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.
Read More